Key result
Dividing the QT interval into its components (QRS, J-Tpeak, Tpeak-Tend) and PR interval can identify which hERG blockers also have calcium and/or sodium channel blocking activity.
Why the study?
Does dividing the QT interval into its components (QRS, J-Tpeak, Tpeak-Tend, PR) determine which hERG potassium channel blockers also have calcium and/or sodium channel blocking activity?
Population
Clinical and preclinical data from 34 studies submitted to the US Food and Drug Administration, alongside…
Design
Other
Authors
Loading...
May refine torsade risk assessment among hERG blockers; hypothesis-generating and requires validation before clinical adoption.
Does dividing the QT interval into its components (QRS, J-Tpeak, Tpeak-Tend, PR) determine which hERG potassium channel blockers also have calcium and/or sodium channel blocking activity?
Dividing the QT interval into specific components may better differentiate dangerous hERG blockers from those with minimal torsade de pointes risk, potentially preventing safe drugs from being labeled unsafe.
Johannesen et al. (2013) studied Drug-induced QT prolongation and torsade de pointes. Dividing the QT interval into its components (QRS, J-Tpeak, Tpeak-Tend) and PR interval was evaluated on Identification of hERG potassium channel blockers that also have calcium and/or sodium channel blocking activity. Dividing the QT interval into its components (QRS, J-Tpeak, Tpeak-Tend) and PR interval can identify which hERG blockers also have calcium and/or sodium channel blocking activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: